secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2026-08-12T12:12:12+00:00
Accession:  0001104659-26-094533
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q2 2026: Net loss $34.6M, cash $197.2M, CNTY-813 IND on track for 4Q26
--------------------------------------------------------------------------------

- Q2 2026 net loss $34.6M vs $32.5M in Q2 2025; R&D $19.6M (down from $26.9M), G&A $5.8M (down from $7.8M).
- Cash, equivalents and investments $197.2M at June 30, 2026, up from $117.1M at Dec 31, 2025; runway into 1Q 2029.
- FDA pre-IND alignment for CNTY-813; IND submission on track for 4Q 2026, initial data expected 2H 2027.
- CNTY-308, CD19-targeted CAR-iT therapy with Allo-Evasion 5.0, remains on track to enter clinic in 2026.
- Preclinical data at ADA 2026 showed durable glucose control >8 months; oral presentations at EASD and CRC 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/0001104659-26-094533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer